Phase II
InflaRx reported additional in-depth analysis of the completed double blind, placebo controlled part of the ongoing international SHINE Phase IIb study to supplement InflaRx’s top line disclosure of results reported on June 5, 2019.
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
A disproportionate number of ALS patients on the investigational drug developed pneumonia.
Phase 1/2 trial to be HOOKIPA’s first clinical trial in immuno-oncology
In late June, Minovia Therapeutics dosed the first patient in a Phase I/II clinical trial with Pearson syndrome. The company is one of the first to make headway in treating rare mitochondrial diseases.
The beginning of virtual clinical trials is going to be a game-changer. Why they are going to be game-changer? What changes will occur? Know it all here.
It was a typically busy week for clinical trials, with announcements in a wide variety of indications. Here’s a look.
PRESS RELEASES